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Editorial: palliative long-term abdominal drains in refractory ascites – a step in the right 
direction, but not the complete solution.  Authors' reply 
Lucia Macken, Stephen Bremner, David Sheridan and Sumita Verma, on behalf of the 
REDUCe study team. 
We thank Dr Hudson for his balanced and insightful editorial (1). We are in agreement that 
palliative care remains woefully inadequate in end-stage liver disease. Reasons are multiple 
and complex but include lack of evidence-based interventions. The REDUCe study (2) 
addressed feasibility to proceed to a definitive trial, our ultimate aim being to improve 
palliative management of refractory ascites in end-stage liver disease.  
Primary prophylaxis for spontaneous bacterial peritonitis remains a contentious issue and is 
the subject of ongoing studies (ASEPTIC EurdaCT number 2019-000581-38). Guidance is to 
use antibiotic prophylaxis in advanced liver disease if ascitic fluid protein is < 15 g/L (3-4). 
Recent studies however suggest that ascitic fluid protein may not predict spontaneous 
bacterial peritonitis (5-6). Nonetheless, there is consensus that severe liver disease is a risk 
factor for spontaneous bacterial peritonitis (7-8). Since refractory ascites reflects advanced 
liver disease with a median survival of six months (3, 9), in our feasibility study, we 
pragmatically offered all research participants prophylactic antibiotics for the study duration. 
Discussions with Hepatologists and Palliative Care specialists who had experience in using 
LTAD in end-stage liver disease supported this strategy. We do nonetheless acknowledge 
that antibiotic use is not without risks. 
Having demonstrated feasibility, the next step would be a definitive study comparing LTAD 
versus large volume paracentesis in refractory ascites due to end-stage liver disease. Since 
infection remains a major deterrent to use of LTAD in cirrhosis, an appropriate primary 
outcome would be non-inferiority peritonitis incidence, with quality of life as one of the 
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secondary outcomes. We would again support use of prophylactic antibiotics in study 
participants, thus assessing incidence of spontaneous bacterial peritonitis after primary 
prophylaxis. The overarching goal, as endorsed by our service users, is to avoid repeated 
hospitalisation. 
Dr Hudson makes a valid point that use of LTAD is only part of the solution in end-stage 
liver disease. We however hope that the feasibility and any potential future definitive trial 
will encourage wider discussions amongst hospital and community teams, thus increasing 
knowledge, skills and confidence in managing end-stage liver disease in the community. It 
could also raise the profile of this disenfranchised cohort, promoting equality in end of life 
care and initiating discussions about future research priorities.                                                                            
The authors' declarations of personal and financial interests are unchanged from those in the 
original article (2). 
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